Posted by Michael Wonder on 18 Jan 2019
Thousands of adults with chronic lymphocytic leukaemia to benefit from new treatment option
18 January 2019 - Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory chronic lymphocytic leukaemia.
Chronic lymphocytic leukaemia is the most common form of leukaemia, with approximately 3,500 new cases diagnosed each year in the UK.
It is estimated that around 1,000 people will be eligible for venetoclax in the first year and will be able to receive the treatment through the NHS.
